Literature DB >> 27416992

Are Short-term Outcomes of Hip Arthroscopy in Patients 55 Years and Older Inferior to Those in Younger Patients?

Andrew J Bryan1, Aaron J Krych1, Ayoosh Pareek1, Patrick J Reardon1, Rebecca Berardelli1, Bruce A Levy2.   

Abstract

BACKGROUND: Hip arthroscopy for young patients with femoroacetabular impingement (FAI) has been successful, but the efficacy of hip arthroscopy in older patients is not clearly defined.
PURPOSE: To evaluate the clinical outcomes of patients 55 years and older who are undergoing hip arthroscopy and to compare outcomes with those of patients younger than 55 years. STUDY
DESIGN: Cohort study; Level of evidence, 3.
METHODS: A total of 201 (63 male, 138 female) patients undergoing primary hip arthroscopy for FAI without radiographic arthritis (Tönnis grade <3) were isolated from a prospective database and stratified by age to <55-year and ≥55-year groups. Patients were evaluated preoperatively and 1 and 2 years postoperatively using the modified Harris Hip Score (mHHS) and Hip Outcome Score (HOS: functional scores, as well as Activities of Daily Living [ADL] and Sport subscales). A Wilcoxon signed rank sum test was used to evaluate the differences in outcome scores between the cohorts at each interval.
RESULTS: The <55-year group included 174 patients (mean age, 37 ± 12 years), and the ≥55-year group included 27 patients (mean age, 61 ± 5 years). The minimum follow-up time was 2 years in each group. Preoperative Tönnis grades and mHHS scores (59 vs 59; P = .75) were similar between groups. The ≥55-year cohort underwent labral debridement more frequently (78% vs 36%; P =.02) and were more likely to have full-thickness cartilage defects (22% vs 4%; P = .04). Despite this, the mHHS in both groups improved significantly from baseline, without significant differences at 1 year (86 [≥55 years] vs 81 [<55 years]; P = .53) or 2 years (73.88 [≥55 years] vs 79.54 [<55 years]; P = .06). However, at a minimum 2-year follow-up, patients <55 years had significant improvements over patients ≥55 years in the HOS subscales for ADL score (85.6 vs 75.2; P = .03), ADL rating (80.1 vs 70.0; P = .004), Sport score (70.2 vs 55.6; P = .04), and Sport rating (70.2 vs 58.0; P = .04).
CONCLUSION: Although younger patients had superior HOS outcomes reported at 2 years compared with older patients after hip arthroscopy for FAI, both groups had significant improvement compared with their baseline. These data suggest that carefully selected patients 55 years and older without radiographic arthritis may benefit from hip arthroscopy.
© 2016 The Author(s).

Entities:  

Keywords:  FAI; hip arthroscopy; labral tear; outcomes

Mesh:

Year:  2016        PMID: 27416992     DOI: 10.1177/0363546516652114

Source DB:  PubMed          Journal:  Am J Sports Med        ISSN: 0363-5465            Impact factor:   6.202


  10 in total

1.  Outcomes of Hip Arthroscopy in the Medicare Patient: A Growing Population.

Authors:  Elizabeth J Scott; Nicholas A Bedard; Christopher West; S Blake Dowdle; Steve S Liu; John J Callaghan
Journal:  Iowa Orthop J       Date:  2019

2.  The minimal clinically important difference for the nonarthritic hip score at 2-years following hip arthroscopy.

Authors:  David A Bloom; Daniel J Kaplan; David J Kirby; Daniel B Buchalter; Charles C Lin; Jordan W Fried; Nainisha Chintalapudi; Thomas Youm
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2021-11-05       Impact factor: 4.342

Review 3.  Refractory pain following hip arthroscopy: evaluation and management.

Authors:  Jason J Shin; Darren L de Sa; Jeremy M Burnham; Craig S Mauro
Journal:  J Hip Preserv Surg       Date:  2018-01-18

4.  Outcomes of Hip Arthroscopy for Femoroacetabular Impingement in Chinese Patients Aged 50 Years or Older.

Authors:  Feng Gao; Baiqing Zhang; Bo Hu; Ming Lu; Mingyang An; Yufeng Liu; Yehan Fang; Gang Zhao; Chao Shi; Jingbin Zhou; Yujie Liu; Chunbao Li
Journal:  Orthop Surg       Date:  2020-05-27       Impact factor: 2.071

5.  Is there a correlation between outcomes after hip arthroscopy for femoroacetabular impingement syndrome and patient cortical bone thickness?

Authors:  Edward C Beck; Kyle N Kunze; Nicole A Friel; William H Neal; Michael C Fu; Brian D Giordano; Jorge Chahla; Shane J Nho
Journal:  J Hip Preserv Surg       Date:  2019-03-15

6.  Arthroscopic hip surgery compared with physiotherapy and activity modification for the treatment of symptomatic femoroacetabular impingement: multicentre randomised controlled trial.

Authors:  Antony J R Palmer; Vandana Ayyar Gupta; Scott Fernquest; Ines Rombach; Susan J Dutton; Ramy Mansour; Simon Wood; Vikas Khanduja; Tom C B Pollard; Andrew W McCaskie; Karen L Barker; Tony J M D Andrade; Andrew J Carr; David J Beard; Sion Glyn-Jones
Journal:  BMJ       Date:  2019-02-07

7.  Functional Outcomes of Arthroscopic Treatment in Femoroacetabular Impingement in Patients over 60 Years Old Compared with Patients Aged 40 Years or Younger.

Authors:  Bernardo Aguilera-Bohórquez; Miguel Brugiatti; Ruddy Coaquira; Orlando Cardozo; Erika Cantor
Journal:  Rev Bras Ortop (Sao Paulo)       Date:  2020-04-02

Review 8.  Evaluation of outcome reporting trends for femoroacetabular impingement syndrome- a systematic review.

Authors:  Ida Lindman; Sarantos Nikou; Axel Öhlin; Eric Hamrin Senorski; Olufemi Ayeni; Jon Karlsson; Mikael Sansone
Journal:  J Exp Orthop       Date:  2021-04-23

9.  Outcome-Affecting Parameters of Hip Arthroscopy for Femoroacetabular Impingement with Concomitant Cartilage Damage-Data Analysis from the German Cartilage Registry.

Authors:  Sebastian Serong; Stefan Fickert; Philipp Niemeyer; Ingo J Banke; Jens Goronzy; Christian Sobau; Wolfgang Zinser; Stefan Landgraeber
Journal:  J Clin Med       Date:  2022-03-10       Impact factor: 4.241

10.  Revision Surgery and Progression to Total Hip Arthroplasty After Surgical Correction of Femoroacetabular Impingement: A Systematic Review.

Authors:  Filippo Migliorini; Nicola Maffulli; Alice Baroncini; Jörg Eschweiler; Markus Tingart; Marcel Betsch
Journal:  Am J Sports Med       Date:  2021-06-03       Impact factor: 6.202

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.